Amc Pharma Limited

Amc Pharma Limited is a small, active company based in London, UK, established thirteen years ago in 2011. With £199,658 in assets and a real address at 14 Chichester Way, it’s managed by one director and one owner, Edwin Mischke. The company operates in multiple sectors, including food product manufacturing, wholesale trade, and online retail, and is classified as an irregular importer of pharmaceutical products, with its last import activity occurring over five years ago in June 2019.

The company's website, AMC Holdings, focuses on supporting scientists, clinicians, and patients by supplying plant-inspired medication and novel product candidates. It partners with MGC Pharmaceuticals, Inc., concentrating on products undergoing U.S. clinical trials, including CimetrA, CannEpil, CogniCann, and ArtemiC. The website highlights its focus on epilepsy, dementia, COVID-19, and Crohn’s disease, and arranges for researchers and physicians to join existing clinical trials. The website also mentions a showroom in Harrods, London.

Financially, Amc Pharma Limited presents a mixed picture. While current assets increased slightly to £200,000, net assets decreased significantly to -£54,000, and net current assets liabilities turned positive to £43,000. Cash bank on hand plummeted 93% to just £37, with creditors increasing by 24% to £100,000. Debtors also rose substantially, with current financial instruments increasing by 13% and non-financial instruments soaring by 250%. Equity saw a substantial improvement, with retained earnings accumulating losses decreasing by 59%. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) allows for agility, but the decrease in equity and cash reserves suggests it’s burning through money. As a small company, it’s exempt from an audit, so the figures are unaudited.

Registered in England/Wales under the registration number 07675886, with a registered address at E14 3EG, England, London, 14 Chichester Way.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.